Why has there been a global surge of new Covid variant NB.1.8.1?
Cases have now been reported in Asian countries such as Thailand, Indonesia and China, while the UKHSA recorded the first 13 cases in England last week.
However, the true numbers are unlikely to be known, given the significant decrease in the number of people testing compared to the figures seen during the global pandemic five years ago.
NB.1.8.1 stemmed from the Omicron variant and was first detected in January this year.
It has quickly spread across China and Hong Kong, and has now been recorded in several states across the United States and Australia.
By late April, NB.1.8.1 comprised about 10.7 per cent of submitted sequences globally, according to the World Health Organization (WHO). This rose from just 2.5 per cent one month before.
The WHO declared the NB.1.8.1 strain a 'variant under monitoring' on 23 May, which means scientists believe it could potentially affect the behaviour of the virus.
Lara Herrero, a virologist from Griffith University in Australia, suspects that NB.1.8.1 spreads more easily than other variants.
'Using lab-based models, researchers found NB.1.8.1 had the strongest binding affinity to the human ACE2 receptor of several variants tested, suggesting it may infect cells more efficiently than earlier strains,' Dr Herrero wrote last month in The Conversation.
Dr Chun Tang, GP at Pall Mall Medical, added: 'NB.1.8.1 isn't too different from the Omicron variant, but it does have some tweaks to its spike protein, which might make it spread a bit more easily or slip past some of our existing immunity.
'That said, early signs suggest it doesn't seem to cause more serious illness, but of course, we're still learning more about it.'
'Its spread has been identified in around 22 countries,' said Dr Naveed Asif, GP at The London General Practice.
'The WHO assesses the additional risk to the global public as currently low, and existing Covid-19 vaccines are considered effective in preventing severe disease.'
However, Nimbus does appear to be more transmissible than previous variants, with notable increases reported in India, Hong Kong, Singapore, and Thailand, notes Dr Asif.
Common symptoms of the NB.1.8.1 variant include a severe sore throat. fatigue, mild cough, fever, muscle aches and congestion.
It has also been reported that some patients have experienced gastrointestinal symptoms such as nausea and diarrhoea.
Healthcare experts have stressed, however, that there is no evidence that the new strain is more deadly or serious than previous variants, and that current Covid vaccines are expected to remain effective and protect anyone infected from severe illness.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
26 minutes ago
- Business Wire
Feinstein Institutes Researchers Find COVID-19 Vaccine Boosters Offer Significant Protection for Cancer Patients
BUSINESS WIRE)--Approximately 81 percent of the U.S. population received at least one dose of the COVID-19 vaccine, and now, researchers from Northwell Health's Feinstein Institutes for Medical Research found that COVID-19 vaccine booster shots provide important protection against severe COVID-19 illness with hospitalization for people living with cancer. The retrospective cohort study, published today in JAMA Oncology, observed over 70,000 patients across four U.S. health systems — including Northwell — and examined the effectiveness of both the monovalent (original) and bivalent (updated) COVID-19 boosters. They found that both boosters significantly reduced COVID-19 hospitalizations. 'COVID-19 vaccines can offer another layer of protection for individuals navigating cancer treatment,' said James M. Crawford, MD, PhD, professor in the Institute of Health System Sciences at the Feinstein Institutes and co-PI of the study. 'This research provides critical information for doctors and patients making decisions about COVID-19 vaccination, especially for vulnerable groups.' The study showed that the both the monovalent and bivalent boosters reduced hospitalizations for whom by nearly 30 percent. While these boosters were effective, the study also revealed a concerning trend: booster uptake among cancer patients was lower than expected, with 69 percent receiving the monovalent booster and only 38 percent receiving the bivalent booster. 'Dr. Crawford and his team's research provides vital knowledge that could help protect the health and well-being of immunocompromised people, like those living with cancer,' said Ping Wang, MD, professor and chief scientific officer and senior vice president at the Feinstein Institutes. 'This study highlights the value of vaccination, particularly for those most vulnerable to serious illnesses.' The study also compared the effectiveness of the boosters in cancer patients to their effectiveness in people without compromised immune systems. While the percentage reduction in hospitalizations was similar between the two groups, the number of people who needed to be vaccinated to prevent a single hospitalization was much smaller for cancer patients. About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn.
CNBC
2 hours ago
- CNBC
'I used to be terrible with money': 39-year-old went from living 'paycheck to paycheck' to earning nearly $900,000 last year
Even as a child, Dr. Anna Chacon knew she wanted to follow in her father's footsteps and pursue a career in medicine. She was drawn to the idea that her skills and knowledge could help people. "I observed my father a lot. I went to work with him. I would study on his lap. He had to study many hours as a physician, and I really liked it," the 39-year-old tells CNBC Make It. Chacon made her childhood dream come true in 2012, when she graduated from Brown University's Warren Alpert Medical School. She attended Brown for her undergraduate degree as well, studying economics. Now, she runs her own private dermatology practice in Coral Gables, Florida, just outside of Miami where she grew up. In addition to seeing patients at her clinic, Chacon works with several hospital networks to provide telehealth services to patients around the country. She earned around $896,000 in 2024 through her own practice, contract work through other hospitals, rental income and brand partnerships. Though she "used to be bad with money," she says, Chacon has built a small dermatology empire, as well as an investment portfolio worth over $3.2 million, bringing her total net worth to around $6 million, including the two properties she owns. Her pathway to success wasn't easy, though. She was often discouraged by people who didn't believe she could be successful in medicine or running her own practice, especially as a minority. "When I told people I wanted to do dermatology or be a physician, I was met, unfortunately, with a lot of discouragement because it was very competitive," she says. "I was told to do something else or that I wouldn't get in, and that actually just encouraged me to work harder." After finishing her residency, Chacon worked as a staff dermatologist at the Cleveland Clinic in Weston, Florida. Her father worked at a nearby hospital, but was laid off at the beginning of the Covid-19 pandemic. "It was a shock for me and everyone else in the family, but it inspired me to know that I couldn't rely on one source [of income]," she says. "As comforting as it sometimes is to work for a big hospital system, a pandemic can happen at any time, and you can go through something unexpected." So, in September 2021, Chacon decided to open her own practice where she could expand her patient list and work on her own terms. From there, she obtained licensure in all 50 states, plus the District of Columbia, Puerto Rico and Guam, a lengthy process that cost around $180,000, she says. Costs included travel, fees for things like background checks and professional assistance. "I wanted that ability to work from anywhere," Chacon says. Her father's layoff not only inspired Chacon to start her own practice, but also to get serious about saving. "I used to be terrible with money. I didn't know how to save. I didn't know how to take advantage of retirement accounts," she says. "Growing up in Miami, there's a lot of focus on materialism … I pretty much lived day by day and paycheck to paycheck." Running her own practice helped Chacon boost her income, but to get better at managing her finances, she started educating herself about investing, including reading outlets like CNBC and The Wall Street Journal, she says. She also downloaded an app to track and manage her finances all in one place. "When I initially started tracking my net worth, I was shocked at how low it was," Chacon says. "My one regret is I didn't start sooner. Most of my growth has actually been in the past five years." Although she didn't have much saved, Chacon was lucky to be debt-free — she didn't even own a credit card when she finished her residency. Her parents and scholarships helped pay for her schooling, so she didn't have student debt either. In 2022, Chacon purchased an office building in Coral Gables for $1.1 million. She put around $300,000 down and paid off the mortgage in 2023. Her practice occupies a portion of the building and she rents out the rest to a medical spa that pays her $7,500 a month. The next year, she purchased a home in Pinecrest, Florida, for $1.9 million. She paid off the mortgage in early 2025, but has never actually lived in the house, choosing instead to continue living with her family and renting out the property for $7,500 a month. She spent a lot of time away from her family while she was in residency in Los Angeles, so she's happy to get plenty of time with them now. "I'm proud to [live with them]," she says. "I want to spend every moment I can with them. I want to learn from them ... I also think it's kind of a waste of money for me to move out because I'm single." Despite earning a high income, Chacon doesn't spend too much beyond her needs. "I try to immerse myself into how to invest properly, and I also try to save for another pandemic because of what my family went through and what we all went through just a few years ago," she says. "I also have gotten just more modest as a physician. A lot of my patients live below the poverty line." She'll occasionally splurge on clothes and shoes when sales are good, she says, but she's trying to rein in her shopping. Here's how she spent her money in April 2025. Chacon also paid around $27,000 for some business expenses, including licensure renewals, tech equipment, marketing and legal fees, subscriptions and services. Chacon pays her family $3,000 a month as a contribution to rent and groceries, as well as payment for some administrative help and errands her family members do for her. Because of that, her personal food budget is often on the low side. She doesn't make regular monthly contributions to her savings and investment accounts, but she front-loaded her retirement accounts at the beginning of the year with contributions totaling $170,000. Chacon prioritizes travel. She'll often add leisure time into her work trips to to maximize her time away from home, she says. She also flies business class most of the time so she can do computer work during flights, she says. Chacon's practice is open 24/7 and she works 80 to 120 hours a week, so she doesn't have much free time. While she recognizes she won't be able to maintain this busy pace forever, "I never want to retire," she says. "I love working. I wouldn't be here if I didn't love to work." Still, she's continuing to save and invest for the future so she can maintain her independence and have the financial means to make decisions "when I want to on my own terms," she says. Ultimately, she wants to make sure she and her family are taken care of and can weather any surprises or downturns that could come their way. She hopes to expand her practice in the future to create something "on a national level." "I want to be known as 'America's dermatologist' that can practice everywhere, because ideally I want to have the biggest reach possible," she says.
CNBC
4 hours ago
- CNBC
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
Swiss pharmaceutical firm Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio, as it looks to shift reliance away from its Entresto heart failure therapy. Sales of Kisqali, which treats metastatic breast cancer, surged 64% globally on a constant currency basis in the three months to June, the company said in its second-quarter sales report. That includes 100% growth in the U.S. It follows a 56% increase in Kisqali sales in the first quarter to March. Speaking on an earnings call, CEO Vas Narasimhan said Kisqali was the drug with the greatest scope for outperformance. Global breast cancer diagnoses and deaths are projected to increase by 2050, according to the World Health Organization's cancer agency, with 1 in 20 women worldwide expected to be diagnosed with breast cancer in their lifetime. That could translate to 3.2 million new cases and 1.1 million deaths a year worldwide by 2050 if current trends continue, the study found — significantly higher than 2022's 2.3 million new cases and 670,000-related deaths. Narasimhan also cited Novartis' "strong pipeline" of other drugs, including its Pluvicto prostate cancer treatment and Scemblix for chronic myeloid leukemia, which he said was also "on track to be a blockbuster." "We continue to drive strong performance on our ongoing launches for Kisqali, Pluvicto, and Scemblix, demonstrating the replacement power in our portfolio," he added in a statement accompanying the results. The comments come as Novartis seeks to shake its reliance on its top-selling Entreso heart failure drug, which faces U.S. patent expiry next year. Entresto brought in $7.8 billion in 2024, accounting for around 15% of the company's overall global sales. It said Thursday that it expects generic drug makers to begin producing copycat versions of the drug by mid-2025, although that timeline is "subject to ongoing IP [intellectual property] and regulatory litigation." On Wednesday, a U.S. federal judge rejected Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic version of the drug before the patent expires. Sales of Entresto rose 22% in the second quarter, in line with the prior three-month period. "Short-term it's an important product for us," outgoing chief financial officer Harry Kirsch said of Entresto Thursday. "We have IP that we're defending. Should we be successful in further defending our appeal, each month we'll have some nice significant upside," he added. Overall, Novartis' second-quarter net sales rose 11% on a constant currency basis to $14.05 billion, just shy of the $14.18 billion estimated by analysts in an LSEG poll. Quarterly adjusted core operating income, meanwhile, rose 21% to $5.93 billion, slightly above the $5.69 billion expected. Novartis said it now expects full-year core operating income to grow by "low teens," up from "low double-digit" previously, while it retained its forecast for sales growth in the high single digits. The company also announced an up to $10 billion share buyback, citing "confidence" in its mid- and long-term growth.
